Depixus will be participating in the 20th Anniversary of the Discovery on Target Conference from 25 to 28 September, 2023, Boston, USA.

Discovery on Target (DOT) highlights advances in current and emerging “hot” targets and technologies, as well as target validation strategies for the discovery and development of novel therapeutic agents ranging from biologics to small molecules.

Dr Gordon Hamilton, President and CEO, will be talking about how Depixus is accelerating the discovery of such novel therapeutics using its powerful new MAGNA™ technology. Don’t miss his presentation, which is entitled ‘Magnetic force spectroscopy – a novel approach to Improve the hit-to-lead and lead optimization phases of RNA-targeted small-molecule drug discovery’.

Depixus will be participating in the 6th Annual RNA-Targeted Drug Discovery Summit from 12 to 14 December, 2023, Boston, USA.

As one of the most anticipated events on the RNA calendar, the RNA-Targeted Drug Discovery Summit returns this December. This premier, definitive, and most comprehensive forum for the RNA-targeting small molecule community will address remaining challenges, including but not limited to RNA structure and function relationship, functional validation, and the translational route from discovery to pre-clinical and clinical development.

Dr Pascal Beurdeley, SVP Product Development, will be talking about how Depixus is accelerating the discovery of such novel therapeutics using its powerful new MAGNA™ technology. Don’t miss her presentation, which is entitled ‘Structure-activity relationships: using magnetic force spectroscopy to link in vivo and in vitro data in RNA-targeted small molecule drug discovery.’